Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study

doi:10.1016/0006-8993(80)90952-X

Brain Research

Volume 193, Issue 1, 7 July 1980, Pages 153-163

https://doi.org/10.1016/0006-8993(80)90952-X Get rights and content

Abstract

Repeated high doses (25 and 100 mg/kg) of methylamphetamine produce long-term depletions of both dopamine (DA) and serotonin (5-HT) in the rat brain. In the DA system, depletions are most pronounced in the neostriatum and substantia nigra, with decreased levels in these two regions being significantly correlated. Within the 5-HT system, levels are most reduced in the amygdala, frontal cortex and neostriatum. When both the DA and 5-HT depleting actions of methylamphetamine are considered, the hypothalamus stands out as one of the more resistant brain regions. The regional pattern of reduced 5-HT levels following methylamphetamine is similar to that seen after p-chloroamphetamine. After both methylamphetamine and p-chloroamphetamine, a loss of 5-HT synaptosomal uptake sites occurs. Serotonergic systems are more sensitive than DA systems to the apparent neurotoxic actions of methylamphetamine.

Reference (35)

ColeS.O.
Brain mechanisms of amphetamine-induced anorexia, locomotion and stereotopy: a review
Neurosci. Biobehav. Rev.
(1978)
GornallA.G. et al.
Determination of serum proteins by means of the Biuret reaction
J. biol. Chem.
(1949)
HeffnerT.G. et al.
Synthesis of catecholamines from [³H]tyrosine in brain during the performance of operant behavior
Brain Research
(1980)
KoganF.J. et al.
Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels
Europ. J. Pharmacol.
(1976)
LeesA.J. et al.
Serotonergic involvement in behavioral responses to amphetamine at high dosage
Neuropharmacology
(1979)
LowryO.H. et al.
Protein measurements with Folin phenol reagent
J. Biol. Chem.
(1951)
MassariV.J. et al.
Evaluation of the effect of p-chloroamphetamine on individual catecholaminergic nuclei in the rat brain
Europ. J. Pharmacol.
(1978)
SeidenL.S. et al.
Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys
Drug Alcohol Depend.
(1976)
WagnerG.C. et al.
Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine
Brain Research
(1980)
WagnerG.C. et al.
Methamphetamine induced changes in brain catecholamines in rats and guinea pigs
Drug Alcohol Depend.
(1979)

EllisonG. et al.

Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration

Science

(1978)

FeliceL.J. et al.

Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography

J. Neurochem.

(1978)

FullerR.W.

Neurochemical effects of serotonin neurotoxins: an introduction

Ann. N.Y. Acad. Sci.

(1978)

FuxeK. et al.

Effects of 6-OH-DA lesions of the ascending noradrenaline and adrenaline pathways to the tel and diencephalon on FSH, LH and prolactin secretion in the ovariectamized female rat

GiambalboC.T. et al.

Effect of p-chloroamphetamine and 5,7-dihydroxytryptamine on rotation and dopamine turnover

Brain Research

(1978)

HarveyJ.A.

Neurotoxic action of halogenated amphetamines

Ann. N.Y. Acad. Sci.

(1978)

HarveyJ.A. et al.

p-Chloroamphetamine: selective neurotoxic action in brain

Science

(1975)

Cited by (446)

Effects of the designer drug 4-methylamphetamine on core temperature and serotonin levels in the striatum and hippocampus of rats
2024, Neuroscience Letters
New psychoactive substances (NPS) are typically synthesized in clandestine laboratories in an attempt to chemically modify already federally regulated drugs in an effort to circumvent the law. Drugs derived from a phenethylamine pharmacophore, such as 4-chloroamphetamine and 3,4-methylenedioxymethamphetamine (MDMA), reliably induce thermogenesis and serotonergic deficits in the striatum and hippocampus of rodents. 4-methylamphetamine (4-MA), a relative newcomer to the NPS scene, was originally investigated in the mid-1900 s as a potential anorexigenic agent. With its phenethylamine pharmacophore, 4-MA was hypothesized to produce similar toxicological alterations as its chemical analogs. In the present study, three doses (1.0, 2.5, and 5.0 mg/kg, ip.) of 4-MA were administered to rats twice daily for two days. Core temperature data were calculated and analyzed as temperature area under the curve (TAUC). On the second day of dosing, a hypothermic response to 4-MA (2.5 and 5.0 mg/kg) was noted between 0.5 and 2.0 h post-treatment. Only the highest dose of 4-MA decreased body weight on the second day of treatment and maintained this reduction in weight for seven days after treatment ceased. None of the doses of 4-MA evaluated significantly altered serotonin levels in the hippocampus or striatum seven days after final treatment. The present findings demonstrate that the 4-methyl substitution to amphetamine generates a pharmacological and toxicological profile that differs from other similar phenethylamine analogs.
Long-term effects of young-adult methamphetamine on dorsal raphe serotonin systems in mice: Role of brain-derived neurotrophic factor
2021, Brain Research
To assess the long-term effects of chronic adolescent methamphetamine (METH) treatment on the serotonin system in the brain, we used serotonin-1A receptor (5-HT_1A) and serotonin transporter (SERT) autoradiography, and quantitative tryptophan-hydroxylase 2 (TPH2) immunohistochemistry in the raphe nuclei of mice. Because of the modulatory role of brain-derived neurotrophic factor (BDNF) on the serotonin system and the effects of METH, we included both BDNF heterozygous (HET) mice and wildtype (WT) controls. Male and female mice of both genotypes were treated with an escalating METH dose regimen from the age of 6–9 weeks. At least two weeks later, acute locomotor hyperactivity induced by a 5 mg/kg D-amphetamine challenge was significantly enhanced in METH-pretreated mice, showing long-term sensitisation. METH pretreatment caused a small, but significant decrease of 5-HT_1A receptor binding in the dorsal raphe nucleus (DRN) of males independent of genotype, but there were no changes in the median raphe nucleus (MRN) or in SERT binding density. METH treatment reduced the number of TPH2 positive cells in ventral subregions of the rostral and medial DRN independent of genotype. METH treatment selectively reduced DRN cell counts in BDNF HET mice compared to wildtype mice in medial and caudal ventrolateral subregions previously associated with panic-like behaviour. The data increase our understanding of the long-term and selective effects of METH on brain serotonin systems. These findings could be relevant for some of the psychosis-like symptoms associated with long-term METH use.
Methamphetamine persistently increases alpha-synuclein and suppresses gene promoter methylation within striatal neurons
2019, Brain Research
Methamphetamine (Meth) produces a variety of epigenetic effects in the brain, which are seminal to establish long-lasting alterations in neuronal activity. However, most epigenetic changes were described by measuring the rough amount of either histone acetylation and methylation or direct DNA methylation, without focusing on a specific DNA sequence. This point is key to comprehend Meth-induced phenotypic changes, brain plasticity, addiction and neurodegeneration. In this research paper we analyze the persistence of Meth-induced striatal synucleinopathy at a prolonged time interval of Meth withdrawal. At the same time, Meth-induced alterations, specifically within alpha-synuclein gene (SNCA) or its promoter, were evaluated. We found that exposure to high and/or prolonged doses of Meth, apart from producing nigro-striatal toxicity, determines a long-lasting increase in striatal alpha-synuclein levels. This is consistent along immune-blotting, immune-histochemistry, and electron microscopy. This was neither associated with an increase of SNCA copy number nor with alterations within SNCA sequence. However, we documented persistently demethylation within SNCA promoter, which matches the increase in alpha-synuclein protein. The amount of the native protein, which was measured stoichiometrically within striatal neurons, surpasses the increase reported following SNCA multiplications. Demethylation was remarkable (ten-fold of controls) and steady, even at prolonged time intervals being tested so far (up to 21 days of Meth withdrawal). Similarly alpha-synuclein protein assayed stoichiometrically steadily increased roughly ten-fold of controls. Meth-induced increase of alpha-synuclein was also described within limbic areas. These findings are discussed in the light of Meth-induced epigenetic changes, Meth-induced phenotype alterations, and Meth-induced neurodegeneration.
Leakage of the blood-brain barrier followed by vasogenic edema as the ultimate cause of death induced by acute methamphetamine overdose
2019, International Review of Neurobiology
Methamphetamine (METH) is a potent CNS stimulant that is widely used as a recreational drug. Due to its ability to increase bodily heat production and diminish heat loss due to peripheral vasoconstriction, METH is able to increase brain and body temperature. The hyperthermic effects of METH are potentiated when the drug is used under conditions of psycho-physiological activation and in warm ambient temperatures. In this short review, we present and discuss our data on the effects of METH on brain temperature and a number of neural parameters that characterize permeability of the blood-brain barrier (albumin immunoreactivity), glial activity (GFAP immunoreactivity), brain tissue water content, and structural abnormalities of brain cells. We demonstrate that the extent of these neural alterations strongly depends on METH-induced brain temperature elevation and they all dramatically increase following exposure to METH in warm (29 °C) vs. standard (23 °C) ambient temperatures. Based on these data we consider possible pathophysiological mechanisms underlying acute METH toxicity, suggesting the critical role of drug-induced brain hyperthermia, temperature-dependent leakage of the blood-brain barrier (BBB), and the development of vasogenic edema that could finally result in decompensation of vital functions and death.
HIV-1 Tat and methamphetamine co-induced oxidative cellular injury is mitigated by N-acetylcysteine amide (NACA) through rectifying mTOR signaling
2018, Toxicology Letters
Methamphetamine (Meth) is an addictive psychostimulant whose abuse is intimately linked to increased risks for HIV-1 infection. Converging lines of evidence indicate that Meth also aggravates the symptoms of HIV-associated neurocognitive disorders (HAND), though the underlying mechanisms remain poorly understood. By using the lipophilic antioxidant N-acetylcysteine amide (NACA) as an interventional agent, we examined the roles of oxidative stress in autophagy and apoptosis induced by HIV-Tat (the transactivator of transcription), Meth or their combined treatment in human SH-SY5Y neuroblastoma cells and in the rat striatum. Oxidative stress was monitored in terms of the production of intracellular reactive oxygen species (ROS) and antioxidant reserves including glutathione peroxidase (GPx) and Cu,Zn-superoxide dismutase (SOD). NACA significantly reduced the level of ROS and restored GPx and SOD to levels comparable to that of normal control, implying a cytoprotective effect of NACA against oxidative stress elicited by Tat- and/or Meth. Protein expression of mammalian target of rapamycin (mTOR) was measured in SH-SY5Y cells and in the rat striatum to further explore the underlying mechanism of NACA protect against oxidative stress. The results support a beneficial effect of NACA in vivo and in vitro through rectification of the mTOR signaling pathway. Collectively, our study shows that NACA protects against Meth and/or Tat-induced cellular injury in vitro and in the rat striatum in vivo by attenuating oxidative stress, apoptosis and autophagy, at least in part, via modulation of mTOR signaling.
The impact of methamphetamines in patients with traumatic brain injury, a retrospective review
2018, Clinical Neurology and Neurosurgery
Citation Excerpt :
Aside from behavioral changes, on the other hand, studies are also investigating the cellular effects of METH in the setting of TBI as well as rehabilitative properties [6–9]. METH can be neurotoxic, damaging dopamine secreting cells of the midbrain and fine axonal terminals [10]. In the setting of TBI, METH can induce central and systemic hyperthermia, increased permeability of the blood brain barrier (BBB) and cerebral edema, all of which can contribute to the devastating effects from secondary brain injury in TBI [6,11].
Both neurotoxic and neuroprotective effects of methamphetamines (METH) are being studied. There are few studies evaluating the effects of METH on patients with traumatic brain injury (TBI). The objective of this study is to compare clinical outcomes after TBI in METH users versus non-METH users.
A retrospective review of 304 patients with severe traumatic head injury were performed. Patients were evaluated and stratified based on toxicology screening for methamphetamines (METH) or none. Of the patients reviewed with a full toxicology, 24 of those patients were positive for METH, and 60 patients were negative. Patients were evaluated based on demographics, type of injury, Glasgow Coma Scale (GCS), and Glasgow Outcome Scale (GOS).
METH patients were younger upon presentation (43.5 versus 55.8, p = 0.003), with a larger improvement in GCS and GOS upon discharge (P = 0.012, 0.0001 respectively). There was no significant difference in length of hospital stay, initial presenting GCS and GOS, or discharge GCS and GOS.
Our findings demonstrate an improved change in GCS and GOS for those positive with METH than those without. Surprisingly, substance positive patients did not have a worse outcome score. Further investigation is necessary to evaluate the potential neuro-protective effects of METH in TBI.

View all citing articles on Scopus

View full text

Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study

Abstract

Neurosci. Biobehav. Rev.

J. biol. Chem.

Brain Research

Europ. J. Pharmacol.

Neuropharmacology

J. Biol. Chem.

Europ. J. Pharmacol.

Drug Alcohol Depend.

Brain Research

Drug Alcohol Depend.

Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration

Science

Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography

J. Neurochem.

Neurochemical effects of serotonin neurotoxins: an introduction

Ann. N.Y. Acad. Sci.

Effects of 6-OH-DA lesions of the ascending noradrenaline and adrenaline pathways to the tel and diencephalon on FSH, LH and prolactin secretion in the ovariectamized female rat

Effect of p-chloroamphetamine and 5,7-dihydroxytryptamine on rotation and dopamine turnover

Brain Research

Neurotoxic action of halogenated amphetamines

Ann. N.Y. Acad. Sci.

p-Chloroamphetamine: selective neurotoxic action in brain

Science